The Latin America oral mucositis market was valued at USD 129.21 Million in 2025 and is expected to grow at a CAGR of 6.10%, reaching USD 233.59 Million by 2035. The market is advancing due to growing cancer prevalence and efforts to improve supportive oncology care. Rising awareness among medical professionals and the introduction of affordable mucosal treatment options are strengthening regional presence. Collaborations between international and local pharmaceutical companies are fostering accessibility and innovation in treatment approaches.
Base Year
Historical Period
Forecast Period
The market is driven by the increasing prevalence of cancer, rising adoption of chemotherapy and radiotherapy, and growing awareness regarding supportive care, contributing significantly to market expansion.
Key trends include advancements in targeted therapies, increasing use of natural and bio-based formulations, and technological progress in oral care delivery systems, all enhancing treatment outcomes and market development.
Leading market participants are focusing on strategic collaborations, innovative treatment formulations, and clinical research investments to enhance product efficacy and accessibility, thereby strengthening market presence and driving regional growth.
Compound Annual Growth Rate
6.1%
Value in USD Million
2026-2035
*this image is indicative*
Oral mucositis is a widespread complication in cancer therapy, often disrupting nutrition and treatment adherence. The oral mucositis market in Latin America is evolving gradually, supported by expanding oncology services, growing healthcare infrastructure, and increasing availability of advanced care solutions. The market is poised to reach USD 233.59 Million by 2035. Efforts to enhance early diagnosis, implement cost-effective treatment approaches, and improve healthcare access are strengthening regional market growth, while ongoing training and patient education initiatives are promoting awareness and more consistent clinical management.
Rising Pediatric Cancer Incidence Likely to Elevate Market Growth in Latin America
The increasing incidence of pediatric cancer is a key growth driver in the market. According to the Pan American Health Organization (PAHO), an estimated 30,000 children and adolescents under 19 years in Latin America and the Caribbean are projected to be diagnosed with cancer annually, with nearly 10,000 fatalities anticipated. This alarming trend underscores the rising need for effective oral mucositis management, as mucositis is a common side effect of cancer therapies. Consequently, this growing pediatric cancer burden is expected to accelerate market expansion across the region.
Key emerging trends in the market include the increasing adoption of natural bioactive therapies and advancements in regenerative biomaterial innovations.
Rising Adoption of Natural Bioactive Therapies to Enhance the Market Demand
The increasing adoption of natural bioactive formulations for cancer therapy-induced mucositis management is a growing trend in the market. Researchers are emphasizing plant-derived compounds with anti-inflammatory and antioxidant properties to improve patient recovery and reduce treatment costs. In October 2023, a study published in Exploratory Drug Science highlighted the effectiveness of a Brazilian green propolis mucoadherent gel in rapidly healing severe oral mucositis cases among radiotherapy patients. This growing clinical validation of natural products is expected to enhance market growth across Latin America.
Regenerative Biomaterial Innovations Expected to Boost Latin America Oral Mucositis Market Demand
The market is witnessing a growing trend toward the adoption of regenerative biomaterial-based therapies to accelerate mucosal healing and improve patient recovery. In February 2025, a study published in Oncotarget by researchers from the Federal University of Rio de Janeiro demonstrated the promising potential of electrospun poly(lactic-co-glycolic acid) (PLGA) membranes in regenerating chemotherapy-induced oral mucositis lesions. This advancement highlights the region’s increasing focus on bioengineered materials to enhance therapeutic outcomes. Such innovations are expected to strengthen market growth in the coming years.
Hospital Pharmacies Expected to Lead the Market Share by Distribution Channel
Distribution of oral mucositis treatments takes place through several key channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Among these, hospital pharmacies are projected to lead the segment, supported by their strong association with healthcare institutions and availability of prescription-based therapies. Their role in providing specialized medications and ensuring timely patient access to effective treatments strengthens their dominance. In contrast, retail and online pharmacies are witnessing steady growth due to convenience and expanding digital healthcare adoption.
The market is divided into regions such as Brazil, Argentina, Mexico, and others. Among these, Brazil is expected to lead due to its strong clinical research initiatives and growing oncology focus. A notable development includes a Phase II clinical study sponsored by the Instituto Nacional de Câncer, Brazil, evaluating the effectiveness of copaíba-based mouthwash in preventing and treating oral mucositis in oral cancer patients undergoing radiotherapy. The study commenced in January 2025, with primary completion expected in July 2027 and full completion anticipated by February 2028. This research underscores Brazil’s leadership in advancing innovative, evidence-based, and locally derived therapeutic solutions for oral mucositis management.
The key features of the market report comprise funding and investment analysis, clinical trials and pipeline analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Amgen Inc. has expanded its reach in the oral mucositis market through the introduction of innovative biologics like Kepivance (palifermin). The therapy offers significant clinical benefits for patients undergoing bone marrow transplants, addressing the high prevalence of oral mucositis in cancer care. Amgen’s efforts enhance access to advanced supportive treatments and strengthen oncology healthcare infrastructure in the region.
Innovation Pharmaceuticals is a biopharmaceutical company focused on developing novel anti-inflammatory and anti-infective treatments. The company is evaluating the clinical and commercial potential of Brilacidin-OM following Phase 2 results demonstrating notable reductions in severe oral mucositis incidence and duration among patients receiving high-dose cisplatin. IPIX is also analyzing provider and payer landscapes to assess revenue potential and adoption pathways. Emphasizing safety, differentiated efficacy, and strategic alliances, the company aims to strengthen its market entry strategies and expand collaborations across healthcare systems.
Galera Therapeutics Inc. is emerging as a contributor to improved oncology care through the development of advanced therapies targeting radiation-induced oral mucositis. The company’s scientific initiatives focus on reducing treatment-related toxicity and enhancing the overall quality of life for cancer patients. With growing attention on accessible and effective supportive care, Galera’s innovative therapeutic pipeline holds promise for strengthening cancer treatment outcomes across the region.
Soligenix Inc. is expanding its influence in the market through efforts to improve supportive treatments for patients experiencing oral mucositis during cancer therapy. The company’s focus on inflammation control and mucosal healing resonates with the region’s growing need for accessible and effective oncology care. By fostering awareness and research collaborations, Soligenix supports healthcare providers in addressing complications that compromise treatment adherence and patient well-being.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Monopar Therapeutics Inc., Oragenics Inc., Jaguar Health Inc., EpicentRx Inc., and Enzychem Lifesciences.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Country
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share